Purchase this article with an account.
Jugchawin Kanokkantapong, Wensi Tao, Catherine Choi, Ravi Doddapaneni, David T Tse, Daniel Pelaez; A xenograft model for lacrimal gland adenoid cystic carcinoma in mice. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5611.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Lacrimal gland adenoid cystic carcinoma (LGACC) is the most common malignant epithelial tumor with a propensity for perineural invasion and poor prognosis. In order to perform preclinical and molecular studies, an experimental animal model is needed that recapitulates the human disease. The aim of this study was to develop an animal model to allow for the elucidation of the initiating, progression, and therapeutic biomarkers in LGACC.
A xenograft model was produced by injecting LGACC tumor cells harvested from patients and propagated in tissue culture (2x106) into the flank of immunocompromised NSG mice. Normal saline was injected in the same method to control mice. Weight of mice was measured every week after injection of LGACC cells. 12 weeks after injection of LGACC cells, mice bearing tumor growth were euthanized and the mass removed. Histologic examination, immunohistochemical analysis for E-CAD, N-CAD, KI67, C-MYB, Ck-5, Ck-8, GATA4, Human mitochondria were performed.
The LGACC tumor xenograft model was successfully established for three different LGACC cells lines. Weight of experimental mice gradually decrease as an indication of tumor associate cachexia. The results of histologic H&E staining indicated that tumor xenograft possesses typical histological characterization of adenoid cystic carcinoma. The results of immunohistochemistry showed that E-CAD, N-CAD, KI67, C-MYB, Ck-5, Ck-8, GATA4, Human mitochondria expressions in tumor tissue harvested from the immunosuppressed NSG mice were positive, recapitulating the representative molecular characteristic of primary LGACC.
Human LGACC cells engrafted and generated exogenous neoplasms in immunocompromised NSG mice. The tumors presented the molecular characteristics of the tumor cell line and primary malignancy. This protocol is considered as an ideal animal model for preclinical studies of human LGACC in-vivo.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only